NDT Advance Access published online on March 5, 2004
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfh123
© 2004 by European Renal Association - European Dialysis and Transplant Association
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Center for Outcomes Research and Education, Evanston Northwestern Healthcare, Evanston, IL; Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
* To whom correspondence should be addressed. E-mail: d-dobrez{at}northwestern.edu.
Background. Abnormalities of serum calcium, phosphorous and intact parathyroid hormone (PTH) are associated with morbidity and mortality in haemodialysis patients. Pharmacologic parenteral vitamin D administration is used to correct these abnormalities; however, the relationship between vitamin D therapies and hospitalizations has never been addressed. Methods. Healthcare data from January 1999 to November 2001 were analysed for 11 443 adult haemodialysis patients who received at least 10 doses of vitamin D therapy. Multivariate models were used to evaluate the effects of vitamin D therapy on: (i) total number of hospitalizations, (ii) total number of hospital days and (iii) risk of first hospitalization after initiation of vitamin D therapy. Results. When compared with the calcitriol group, the paricalcitol group had a lower risk of first all-cause hospitalization (14% less likely, P<0.0001), fewer hospitalizations per year (0.642 fewer, P<0.001) and fewer hospital days per year (6.84 fewer, P<0.001). In the paricalcitol and calcitriol groups, respectively, 5.6 and 41.3% patients switched to another vitamin D compound. For those patients who started and remained on the same vitamin D product, paricalcitol-treated patients experienced 0.846 fewer hospitalizations per year and 9.17 fewer hospital days per year, P<0.001 for both. The paricalcitol group also had a lower risk of first PTH-related hospitalizations, fewer PTH-related annual hospitalizations and fewer days per year. Conclusion. Paricalcitol-treated patients experienced fewer hospitalizations and hospital days per year when compared with calcitriol-treated patients. Initiating vitamin D therapy with paricalcitol may result in overall savings of
Accepted December 17, 2003
Original Article
Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings
2 Center for Pharmaceutical Appraisal and Outcomes, Abbott Laboratories, Abbott Park, IL, USA
3 Department of Statistics, Abbott Laboratories, Abbott Park, IL, USA
4 Global Renal Project Team, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, USA
5 Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Nephrology and Hypertension, Evanston Northwestern Healthcare, Evanston, IL, USA
Abstract 
\$7600-11 000 per patient per year. A randomized, controlled, blinded study would be valuable in confirming and understanding these results.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. P. How, D. L. Mason, and A. H. Lau Current Approaches in the Treatment of Chronic Kidney Disease Mineral and Bone Disorder Journal of Pharmacy Practice, June 1, 2008; 21(3): 196 - 213. [Abstract] [PDF]
|
|
|
|
|
|
A. B. Pai and T. A. Conner Oxidative Stress and Inflammation in Chronic Kidney Disease: Role of Intravenous Iron and Vitamin D Journal of Pharmacy Practice, June 1, 2008; 21(3): 214 - 224. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Palmer and G. Strippoli Reply: Vitamin D compounds in chronic kidney disease: change may be needed for good! Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1789 - 1792. [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Palmer, D. O. McGregor, P. Macaskill, J. C. Craig, G. J. Elder, and G. F.M. Strippoli Meta-analysis: Vitamin D Compounds in Chronic Kidney Disease Ann Intern Med, December 18, 2007; 147(12): 840 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Q Hudson Secondary Hyperparathyroidism in Chronic Kidney Disease: Focus on Clinical Consequences and Vitamin D Therapies Ann. Pharmacother., September 1, 2006; 40(9): 1584 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Jindal, C. T. Chan, C. Deziel, D. Hirsch, S. D. Soroka, M. Tonelli, and B. F. Culleton CHAPTER 3: Mineral Metabolism J. Am. Soc. Nephrol., March 1, 2006; 17(3_suppl_1): S11 - S15. [Full Text] [PDF]
|
|
|
|
|
|
H. Reichel Current treatment options in secondary renal hyperparathyroidism Nephrol. Dial. Transplant., January 1, 2006; 21(1): 23 - 28. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Razzaque, R. St-Arnaud, T. Taguchi, and B. Lanske FGF-23, vitamin D and calcification: the unholy triad Nephrol. Dial. Transplant., October 1, 2005; 20(10): 2032 - 2035. [Full Text] [PDF]
|
|